AFT's disclosure lacks candour despite chair's pedigree

AFT's disclosure lacks candour despite chair's pedigree
AFT Pharmaceuticals chair David Flacks has a strong background in regulation and governance.
Jenny Ruth
It's hard to fathom that AFT Pharmaceuticals' management and board only realised late on the company's balance date that it was going to miss its earnings guidance by as much as 50%.Founder and managing director Hartley Atkinson assured BusinessDesk that is what happened.AFT has two distinct revenue streams. Licensing agreements and milestone payments are by nature lumpy, and it's easy to understand that Atkinson and his team may have been expecting deals to be signed by March 31, only to see the timing slip a couple of weeks or...

More Markets

Australian shares rally as dollar hits six-month high
Markets Aus Market Wrap

Australian shares rally as dollar hits six-month high

The ASX200 has risen 1.2% to hit a nine-day high.

AAP 7:45am
NZ sharemarket down, Oz and US stocks climb
Markets Market close

NZ sharemarket down, Oz and US stocks climb

The S&P/NZX 50 Index closed at 11,746.66, down 44.26 points or 0.38%.

Graham Skellern 04 Jul 2024
Summerset anticipates flat 1H underlying profit
Markets

Summerset anticipates flat 1H underlying profit

The company is NZ's best-performing retirement village operator.

Gregor Thompson 04 Jul 2024
Infratil's CDC investment cracks $5 billion mark
Markets

Infratil's CDC investment cracks $5 billion mark

Surging datacentre demand and expanded development plans benefit Infratil.